Articles

Comparative analysis of cancer statistics in China and the United States in 2024Comparative analysis of cancer statistics in China and the United States in 2024

Yujie Wu, Siyi He, Mengdi Cao,et al. Chin Med J (Engl) 2024 Dec 20;137(24):3093-3100

https://doi.org/10.1016/j.jncc.2024.06.005 In 2024, there are an estimated 3,246,625 and 2,510,597 new cancer cases and 1,699,066 and 640,038 cancer deaths in China and the US, respectively. The highest estimated cancer cases are lung cancer in China and breast cancer in the US. The age-standardized incidence ra... Read More

23 Mar, 2026

Cancer survival statistics in China 2019-2021: a multicenter, population-based study

Hongmei Zeng, Rongshou Zheng, Kexin Sun et al. J Natl Cancer Cent. 2024 Jun 22;4(3):203-213

A milestone goal of the Healthy China Program (2019-2030) is to achieve 5-year cancer survival at 43.3% for all cancers combined by 2022. To assess the progress towards this target, we analyzed the updated survival for all cancers combined and 25 specific cancer types in China from 2019 to 2021.  In 2019-2021,... Read More

23 Mar, 2026

Cancer incidence and mortality in China, 2022

Bingfeng Han 1, Rongshou Zheng 1, Hongmei Zeng 1, et al. J Natl Cancer Cent. 2024 Feb 2;4(1):47-53

The National Cancer Center (NCC) of China regularly reports the nationwide statistics on cancer incidence and mortality in China. The International Agency for Research on Cancer (IARC) calculates and publishes the cancer burden of countries around the world every two years. NCC has received approval from the Nation... Read More

23 Mar, 2026

Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis

Edward Christopher Dee, Mathieu Laversanne, Nirmala Bhoo-Pathy Lancet Oncol. 2025 Apr;26(4):516-528

Cancer is a leading cause of morbidity and mortality in southeast Asia. We aimed to present and interpret cancer incidence and mortality statistics in the 11 constituent countries of Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Timor-Leste, and Viet Nam to inform research ... Read More

23 Mar, 2026

Global, regional, and national burden of breast cancer among females, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023

GBD 2023 Breast Cancer. The Lancet Oncology. 2026. 27:302-326

In 2023, there were an estimated 2·30 million breast cancer incident cases, 764 000 deaths , and 24·1 million DALYs among females globally. The age-standardised incidence rate (ASIR) was the highest (24·1 per 100 000 [16·8 to 31·9]). The highest ASIR was in the high-income group and the lowest ASMR was in the upper... Read More

23 Mar, 2026

Global burden and risk factors of male cancers from 1990 to 2021, with forecasts to 2040

Youao Zhang, Pinhao Wang, Zixuan Jia,et al. Sci Rep. 2025 Feb 11;15(1):5123

Male cancers, which refers to cancers that occur exclusively in males, is a prevalent type of cancer worldwide, primarily including prostate cancer (PCa) and testicular cancer (TCa). These cancers are significant contributors to the global disease burden. We analyzed Global Burden of Disease (GBD) 2021 on male canc... Read More

23 Mar, 2026

Burden of 30 cancers among men: Global statistics in 2022 and projections for 2050 using population-based estimates

Habtamu Mellie Bizuayehu, Abel F Dadi, Kedir Y Ahmed Cancer 2024 Nov 1;130(21):3708-3723

Men exhibit higher prevalence of modifiable risk factors, such as smoking and alcohol consumption, leading to greater cancer incidence and lower survival rates. The authors analyzed 30 cancer types among men in 2022, with projections estimated for 2050. In 2022, a high MIR (indicating poor survival) was observed am... Read More

23 Mar, 2026

Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050

Yingying Li, Wenfu Song, Ping Gao, et al. BMC Cancer (2025) 25:330

Female breast cancer, cervical cancer, uterine cancer, and ovarian cancer (FBCUO) pose a significant threat to global public health. Data from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2021 provide critical insights that can guide the understanding and management of these cancers. Our stu... Read More

23 Mar, 2026

Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN)

Wei Cao 1, Kang Qin 2, Feng Li 3, Wanqing Chen J Natl Cancer Cent. 2024 May 7;4(2):128-134

The International Agency for Research on Cancer (IARC) released the latest estimates of the global burden of cancer. We present a comparison of cancer profiles between 2020 and 2022, leveraging data from the Global Cancer Statistics (GLOBOCAN). Lung cancer remained the most common cancer and the leading cause of ca... Read More

23 Mar, 2026

Global burden of cancer and associated risk factors in 204 countries and territories, 1980– 2021: a systematic analysis for the GBD 2021

Zenghong Wu, Fangnan Xia and Rong Li. Journal of Hematology & Oncology, (2024)

Cancer is the second most common cause of death globally.This study aimed to assess cancer burden and associated risk factors in 204 countries and territories between 1980 and 2021.Methods We selected data on cancer incidence and mortality rates and associated risk factors from the global burden of disease (GBD) st... Read More

23 Mar, 2026